Generium

Generium is a full-cycle innovative high-end pharmaceutical company with a focus on saving lives and promoting health. Established in 2009, it has emerged as a leader in the Russian orphan pharmaceutical market. The company's core strength lies in its in-house R&D park, capable of handling the entire development cycle of biological drugs, from molecule design to commercial production. Generium is committed to international collaboration in science, partnering with leading biotechnological companies and institutes worldwide.

Generium's manufacturing facilities boast high-end equipment and operate under GMP standards, ensuring readiness to produce a wide range of biological drugs or ATMPs. The company's dedication to their mission — ideas to save life and health — is evident in their approach and strategic investments. While specific details about the last investment and investors are currently unavailable, Generium's commitment to innovation and its significant presence in the biotechnology industry position it as an attractive prospect for potential venture capital investment.